Patient Engagement Program offers help where it’s needed

Support that drives adherence

The OncoguardTM Liver Patient Engagement Program helps empower patients to actively manage their health and stay on top of their scheduled HCC testing.

exsAsset 11

It is estimated that three million patients in the US qualify for HCC surveillance.1 However, overall surveillance utilization is estimated to be less than 30%2

Asset 42

Surveillance rates are highest in patients receiving sub-specialty care from gastroenterology/hepatology clinics; 73.7% (66.6-80.3)2

Asset 43

In center-based studies that included primary care surveillance, utilization occurred in 29.5% (21.1-38.6%)2

Asset 23

Patients report that issues making it more difficult to complete surveillance include:3

  • Difficulties with scheduling
  • Costs associated with surveillance testing
  • Transportation concerns
Asset 41

Providers report that barriers to greater utilization of HCC surveillance include:4

  • Lack of information about benefits
  • Limited time available to spend with patients
  • Competing clinical concerns
  • Under-recognition of cirrhosis or liver disease

The OncoguardTM Liver solution offers a Patient Engagement Program

Patient engagement and outreach programs have been shown to increase patient adherence to HCC surveillance.5,6,7 Tested interventions such as EMR reminders and mailed outreach have demonstrated to increase relative surveillance utilization by 60%-80%.2

Our tailored Patient Engagement Program was designed to help support patients adhere to routine HCC testing through:

exsAsset 56
A welcome brochure available for providers to hand out in their office
exsAsset 54
Testing education mailed to patients following negative OncoguardTM Liver test results
Outreach to remind patients of the importance of ongoing testing 6 months after a negative OncoguardTM Liver test result

Learn about Exact Sciences

Learn more

References: 1. Beste LA, Ioannou GN, Yang Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13(1):172-179. doi:10.1016/j.cgh.2014.04.033 2. Wolf E, Rich NE, Marrero JA, et al. Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology. Published online May 8, 2020; 10.1002/hep.31309. doi:10.1002/hep.31309 3. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875-884. doi:10.1002/hep.28770 4. Simmons OL, Feng Y, Parikh ND, et al. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2019;17(4):766-773. doi:10.1016/j.cgh.2018.07.029 5. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921. doi:10.1158/0008-5472.CAN-14-0155 6. Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol. 2019;11(1):1-18. doi:10.4254/wjh.v11.i1.1 7. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748-755.e3. doi:10.1016/j.cgh.2018.05.057